ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

INDP Indaptus Therapeutics Inc

2.7007
-0.0993 (-3.55%)
Última actualización: 12:48:04
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Indaptus Therapeutics Inc INDP NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.0993 -3.55% 2.7007 12:48:04
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.75 2.65 2.88 2.80
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
04/6/202407:00GLOBEIndaptus Therapeutics to Present New Positive Data on..
03/6/202407:00GLOBEIndaptus Therapeutics Announces New Positive Data from..
30/5/202407:00GLOBEIndaptus Therapeutics to Present at the Jefferies Global..
29/5/202407:00GLOBEIndaptus Therapeutics to Present New Cohort Data Confirming..
22/5/202407:00EDGAR2Form 8-K - Current report
22/5/202407:00GLOBEIndaptus Therapeutics Announces Completion of First Patient..
08/5/202407:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202407:05EDGAR2Form 8-K - Current report
08/5/202407:00GLOBEIndaptus Therapeutics Reports First Quarter 2024 Financial..
11/4/202406:30GLOBEIndaptus Therapeutics Presents Positive Mechanism of Action..
28/3/202407:00GLOBEIndaptus Therapeutics to Present at the MedInvest Biotech..
25/3/202407:30GLOBEIndaptus Therapeutics Previews Positive Mechanism of Action..
18/3/202407:00GLOBEIndaptus Therapeutics to Participate in Tribe Public Webinar..
13/3/202406:30GLOBEIndaptus Therapeutics Reports Fourth Quarter and Year-End..
04/3/202410:01EDGAR2Form 8-K - Current report
04/3/202406:30GLOBEIndaptus Therapeutics Announces Positive Results from Second..
15/2/202407:00GLOBEIndaptus Therapeutics to Present at the 2024 BIO CEO &..
08/2/202407:00GLOBEIndaptus Therapeutics Expands Digital Presence with Launch..
23/1/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202415:05EDGAR2Form 8-K - Current report
04/1/202407:00GLOBEEuropean Patent Office Approves Key Patent for Indaptus..
06/11/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202315:05EDGAR2Form 8-K - Current report
06/11/202315:01GLOBEIndaptus Therapeutics Reports Third Quarter 2023 Financial..
06/11/202307:13EDGAR2Form 8-K - Current report
06/11/202307:00GLOBEIndaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune..
31/10/202308:12EDGAR2Form 8-K - Current report
31/10/202308:01GLOBEIndaptus Therapeutics to Present Positive Pharmacodynamic..
27/9/202307:00GLOBEIndaptus Therapeutics to Present at the LD Micro Main Event..
26/9/202307:00GLOBERegistration Is Now Open For Tribe Public’s Webinar Event..
19/9/202307:00GLOBEIndaptus Therapeutics Doses First Patient in Second Cohort..
06/9/202307:05GLOBEIndaptus Therapeutics to Present at the H.C. Wainwright 25th..
16/8/202317:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202307:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202307:10EDGAR2Form 8-K - Current report
14/8/202307:00GLOBEIndaptus Therapeutics Reports Second Quarter 2023 Financial..
10/8/202307:45EDGAR2Form 8-K - Current report
10/8/202307:45GLOBEIndaptus Therapeutics Announces Opening of Next Cohort in..
07/8/202307:00GLOBEIndaptus Therapeutics Appoints Industry Veteran Roger..
15/6/202307:00GLOBEIndaptus Therapeutics to Participate in the Maxim Group..